



(51) International Patent Classification:

A01K 67/027 (2006.01) *C07K 16/40* (2006.01)
C07K 16/00 (2006.01) *C12N 15/85* (2006.01)

(21) International Application Number:

PCT/US2013/044257

(22) International Filing Date:

5 June 2013 (05.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13/488,628 5 June 2012 (05.06.2012) US

(71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591- (US).

(72) Inventors: **BABB, Robert**; 292 Voorhis Avenue, River Edge, NJ 07661 (US). **MCWHIRTER, John**; 2035 Crescent Drive, Tarrytown, NY 10591 (US). **MACDONALD, Lynn**; 16 Gedney Way, White Plains, NY 10605 (US). **STEVENS, Sean**; 355 Berry Street, #413, San Francisco, CA 94158 (US). **DAVIS, Samuel**; 332 West 88th Street, Apartment B2, New York, NY 10024 (US). **BUCKLER, David, R.**; 6 Erick Court, Chester, NJ 07930 (US). **HOSIAWA, Karolina, A.**; 14 Church Street, 2nd Floor, Tarrytown, NY 10591 (US). **MURPHY, Andrew, J.**; 10 Newton Court, Croton-on-Hudson, NY 10520 (US).

(74) Agent: **KOWALCHYK, Katherine, M.**; Merchant & Gould P.C., P.O. Box 2903, Minneapolis, MN 55402-0903 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS FOR MAKING FULLY HUMAN BISPECIFIC ANTIBODIES USING A COMMON LIGHT CHAIN




FIG. 8

(57) **Abstract:** A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.

